Clinical Study

Neurofunctional Predictors Of Escitalopram Treatment Response In Adolescents With Anxiety

Posted Date: Dec 6, 2017

  • Investigator: Jeffrey Strawn
  • Co-Investigator: Jeffrey Strawn
  • Specialties:
  • Type of Study: Drug

The purpose of this study is study is to explore the biology of generalized anxiety disorder (GAD) using functional brain imaging in patients with GAD and healthy subjects and to determine treatment-related effects of escitalopram on brain functional activity and brain chemicals in pediatric GAD. Escitalopram is FDA-approved to treat major depressive disorder in children and adolescents, but is not FDA approved for generalized anxiety disorder. By completing this study, we hope to better understand who benefits from treatment and why they do or do not respond to medications. With this information, we hope to be able to improve treatment and outcome in people with generalized anxiety disorder.

Criteria:

You Are Being Asked To Take Part In This Research Study Because You Have Been Diagnosed With Generalized Anxiety Disorder. To Participate In This Study You Must Be At Least 12 Years Old And Younger Than 18 Years Of Age.

Keywords:

Adolescent, Anxiety, Mri, Antidepressant, Null

For More Information:

Heidi Schroeder
513-558-4422
heysehk@uc.edu

  • Search Clinical Studies

  • Research in the News

    Enhanced Recovery Program for Colorectal Surgery Patients Reduces Costs

    A standardized protocol for managing patients for the duration of colorectaloperations not only improved clinical outcomes, but also it significantlyreduced hospital costs.